Overview

Efficacy and Safety of Lumiracoxib

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Diclofenac
Lumiracoxib